|
|
|
Stem Cell Related Patent Number US6733743
| Title: | Methods to impair hematologic cancer progenitor cells and compounds related thereto | | Inventors: | Jordan, Craig; Lexington, KY, USA | | Summary: | This invention introduces novel methods of administering a compound that selectively binds to an interleukin-3 receptor alpha chain, thereby causing impairment to the cancer cells. Central to the invention is the discovery that primitive or progenitor hematologic cancer cells have been implicated in the early stages and development of leukemia and malignant lymphoproliferative disorders, including acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML) and chronic lymphoid leukemia (CLL). Disclosed herein are processes by which the interleukin-3 receptor alpha chain (IL-3R?a or CD123) is strongly expressed on progenitor hematologic cancer cells, but is virtually undetectable on normal bone marrow cells. Further described are methods of impairing progenitor hematologic cancer such s leukemia and lymphomic cells by selectively targeting cells expressing CD123 but not CD131. Pharmaceutical compounds that selectively bind to CD123 are included, such as cytotoxic moieites, radioisotopes and chemotherapeutics. Therapeutic applications emphasize the detection and treatment of leukemias and malignant lymphoproliferative disorders. | | Abstract: | | | US Patent Website: | Click Here for Full Text of Patent | | Title Number: | US6733743 | | Application Number: | US2001000799100 | | Date Filed: | 06/03/2001 | | Date Published: | 11/05/2004 | | Assignee: | University of Kentucky Research Foundation, Lexington, KY, USA |
|
|
